A review of hepatitis B vaccination

Expert Opinion on Drug Safety

Volumn 2, Issue 2, 2003, Pages 113-122

  Geier, Mark R ^a   Geier, David A ^b   Zahalsky, Arthur C ^c  

^a Genetic Centers of America   (United States)

^b MedCon Inc   (United States)

^c IMMUNOX Edwardsville   (United States)

Author keywords

aluminium; autoimmune; hepatitis B surface antigen (HBsAg); hepatitis B virus (HBV); thimerosal; VAERS; yeast

Indexed keywords

HEPATITIS B VACCINE;

ADULT; CLINICAL TRIAL; DRUG SURVEILLANCE PROGRAM; HEPATITIS B; HUMAN; IMMUNIZATION; IMMUNOLOGY; REVIEW; VACCINATION;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; CLINICAL TRIALS; HEPATITIS B; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION SCHEDULE; VACCINATION;

EID: 1942482009     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2.2.113     Document Type: Review

References (57)

1. ADVISORY COMMITTEE FOR IMMUNIZATION PRACTICES: Recommendations for protection against viral hepatitis. MMWR (1990) 38(Suppl.).
2. CENTERS FOR DISEASE CONTROL AND PREVENTION: Hepatitis Surveillance Report No. 52. Atlanta: US Department of Health and Human Services, Public Health Service (1989).
3. CENTERS FOR DISEASE CONTROL AND PREVENTION: Hepatitis Surveillance Report No. 51. Atlanta: US Department of Health and Human Services, Public Health Service (1987):9-22.
4. FRANCIS DP, FAVERO MS, MAYNARD JE: Transmission of hepatitis B virus. Semin. Liver Dis. (1981) 1:27-32.
5. FRANCIS DP, MAYNARD JE: The transmission and outcome of hepatitis A, B and non-A, non-B: a review. Epidemiol. Rev. (1979) 1:17-31
6. HEYWARD WL, BENDER TR, MCMAHON BJ et al.: The control of hepatitis B virus infection with vaccine in Yupik Eskimos. Demonstration of safety, immunogenicity, and efficacy under field conditions Am. J. Epidemiol. (1985) 121:914-923.
7. ALTER MJ, HADLER SC, MARGOLIS HS et al.: The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies. JAMA (1990) 263:1218-1222.
8. CENTERS FOR DISEASE CONTROL AND PREVENTION: Changing patterns of groups at high risk for hepatitis B in the United States. MMWR (1988) 37:329-437.
9. GOCKE DJ: A prospective study of posttransfusion hepatitis. JAMA (1972) 219:1165-1170.
10. SEEFF LB, ZIMMERMAN HG, WRIGHT EC et al.: A randomized double blind controlled trial of the efficacy of immune serum globulin for the prevention of post-transfusion hepatitis. A Veterans Administration Cooperative Study. Gastroenterology (1977) 72:111-124.
11. MCLEAN AA, HILLEMAN MR, MCALEER AJ, BUYNAK EB: Summary of worldwide experience with H-B-Vax (B, MSD). J. Infect. (1983) 7(Suppl. 1):95-104.
12. SZMUNESS W, STEVENS CE, HARLEY EJ et al.: Hepatitis B vaccine: demonstration of efficacy in a controlled trial in a high-risk population in the United States. N. Engl. J. Med. (1980) 303:833-841.
13. CROSNIER J, JUNGERS P, COUROUCE AM et al.: Randomized placebo controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units: II. Haemodialysis patients. Lancet (1981) 2:797-800.
14. SZMUNESS W, STEVENS CE, HARLEY EJ: Hepatitis B vaccine in medical staff of hemodialysis units. Efficacy and subtype cross protection. N. Engl. J. Med. (1982) 307:1481-1486.
15. BEASLEY RP, HWANG LY, LEE GC et al.: Prevention of perinatally transmitted hepatitis B virus infection with hepatitis B immune globulin and hepatitis B vaccine. Lancet (1983) 2:1099-1102.
16. COUTINHO RA, LELIE N, ALBREACHVAN LENT P et al.: The efficacy of heat inactivated hepatitis B vaccine in male homosexuals: outcome of a placebo controlled double blind trial. Br. Med. J. (1983) 286:1305-1308.
17. WONG VC, IP HM, REESINK HW et al.: Prevention of the HBsAG carrier state in newborn infants of mothers who are chronic carriers of HBsAG and HbeAg by administration of hepatitis B vaccine and hepatitis B immunoglobulin. Lancet (1984) 1:921-926.
18. CHUNG WK, YOO JY, SUN HS et al.: Prevention of perinatal transmission of hepatitis B virus: a comparison between the efficacy of passive and passive-active immunization in Korea. J. Infect. Dis. (1985) 151:280-286.
19. CHUNG WK, SUN HS, CHUNG KW, KIM BS, MIN BK, PRINCE AM: Safety and immunogenicity of a new heat-inactivated hepatitis B vaccine in adult recipients. Vaccine (1987) 5:175-178.
20. GUST ID, SUTANTO A, MAYNARD JE, WIJAYA A, SOSROAMIDJOJO S: Integration of hepatitis B immunization into the expanded program for immunization: the Lombok experience. In: Progress in Hepatits B Immunization. Coursaget P, Tong MJ, (Eds), John Libby Eurotext, Paris (1990):459-466.
21. EMINI EA, ELLIS RW, MILLER WJ, MCALEER AJ, SCOLNICK EM, GERETY RJ: Production and immunological analysis of recombinant hepatitis B vaccine. J. Infect. (1986) 13(Suppl. A):3-9.
22. STEPHENNE J: Development and production aspects of a recombinant yeastderived hepatitis B vaccine. Vaccine (1990) 8(Suppl.):S69-S73.
23. TRON F, DEGOS F, BRECHOT C et al.: Randomized dose range study of a recombinant hepatitis B vaccine produced in mammalian cells and containing the S and PreS2 sequences. J. Infect. Dis. (1989) 160:199-204.
24. GERETY RJ, WEST DJ: Current and future hepatitis B vaccines. In: Progress in Hepatitis B Immunization. Coursaget P, Tong MJ (Eds), John Libby Eurotext, Paris (1990):215-223.
25. ZAJAC BA, WEST DJ, MCALEER WJ, SCOLNICK EM: Overview of clinical studies with hepatitis B vaccine made by recombinant DNA. J. Infect. (1986) 13(Suppl. A):36-45.
26. ANDRE FE: Summary of safety and efficacy data on a yeast derived hepatitis B vaccine. Am. J. Med. (1989) 87:S14-S20.
27. ANDRE FE: Clinical experience with a recombinant DNA hepatitis B vaccine. Southeast Asian J. Trop. Med. Public Health (1988) 19:501-510.
28. GREENBERG DP: Pediatric experience with recombinant hepatitis B vaccines and relevant safety and immunogenicity studies. Pediatr. Infect. Dis. J. (1993) 12:438-445.
29. GOOLSBY LPG: Erythema nodosum after Recombivax HB hepatitis B vaccine. N. Engl. J. Med. (1989) 21:1198-1199.
30. TREVISAN G, STINCO G: Lichen ruber planus following HBV vaccination. Acta Derm. Venereol. (1993) 73:73.
31. AUBIN F, ANGONIN R, HUMBERT P, AGACHE P: Lichen planus following hepatitis B vaccination. Arch. Dermatol. (1994) 130:1329-1330.
32. ROGERSON S, NYE FJ: Hepatitis B associated with erythema nodosum and polyarthritis. Br. Med. J. (1990) 301:345.
33. HASSAN W, OLDHAM R: Reiter's syndrome and reactive arthritis in health care workers after vaccination. Br. Med. J. (1994) 309:94.
34. VAUTIER G, CARTY JE: Acute seropositive rheumatoid arthritis occurring after hepatitis B vaccination. Br. J. Rheumatol. (1994) 33:991-998.
35. ALLEN MB, CLOCKWELL P, PAGE RL: Pulmonary and cutaneous vasculitis following hepatitis B vaccination. Thorax (1993) 48:580-581.
36. TUDELA P, MARTI S, BONAL J: Systemic lupus erythematosus and vaccination against hepatitis B. Nephron (1992) 62:236.
37. CARMELI Y, OREN R: Hepatitis B vaccine side-effect. Lancet (1993) 341:250-251.
38. MARTINEZ E, DOMINGO P: Evan's syndrome triggered by recombinant hepatitis B vaccine. Clin. Infect. Dis. (1992) 15:1051.
39. POULIN P, GABRIEL B: Thrombocytopenic purpura after recombinant hepatitis B vaccine. Lancet (1994) 344:1293.
40. BREZIN AP, LAUTIER-FRAU M, HAMEDANI M, ROGEAUX O, LEHOANG P: Visual loss and eosinophilia after recombinant hepatitis B vaccine. Lancet (1993) 342:563-564.
41. BREZIN AP, MASSIN-KOROBELNIK P, BOUDIN M, GAUDRIC A, LEHOANG P: Acute posterior multifocal placoid pigment epitheliopathy after hepatitis B vaccine. Arch. Ophthalmol. (1995) 113:297-300.
42. HERROELEN L, DEKEYSER J, EBINGER G: Central nervous system demyelination after immunization with recombinant hepatitis B vaccine. Lancet (1991) 338:1174-1175.
43. TARTAGLINO LM, HEIMANPATTERSON T, GRIEDMAN DP, FLANDERS AE: MR imaging in a case of postvaccination myelitis. Am. J. Neuroradiol. (1995) 16:581-582.
44. NADLER JP: Multiple sclerosis and hepatitis B vaccination. Clin. Infect. Dis. (1993) 17:928-929.
45. DEISENHAMMER F, POHL P, BOSCH S, SCHMIDAUER C: Acute cerebellar ataxia after immunization with recombinant hepatitis B vaccine. Acta Neurol. Scand. (1994) 89:462-463.
46. SINGLETON JA, LLOYD JC, MOOTREY GT, SALIVE ME, CHEN RT: An overview of the Vaccine Adverse Event Reporting System (VAERS) as a surveillance system. Vaccine (1999) 17:2908-2917.
47. GEIER MR, GEIER DA: Arthritic reactions and hepatitis B vaccination: an analysis of the Vaccine Adverse Events Reporting System (VAERS) database from 1990 through 1997. Clin. Exp. Rheumatol. (2000) 18:789-790.
48. GEIER MR, GEIER DA: Hepatitis B vaccine and gastroenterologic reactions. Hepatogastroenterology (2001) 48(37).
49. GEIER MR, GEIER DA: Immunologic reactions and hepatitis B vaccine. Ann. Intern. Med. (2001) 134:1155.
50. GEIER MR, GEIER DA: Hepatitis B vaccination safety. Ann. Pharmacother. (2002) 36:370-374.
51. GEIER DA, GEIER MR: Hepatitis B vaccination and arthritic adverse reactions: a followup analysis of the Vaccine Adverse Events Reporting System (VAERS). Clin. Exp. Rheumatol. (2002) 20:119.
52. GEIER DA, GEIER MR: Hepatitis B vaccination and gastrointestinal adverse reactions: a followup analysis. Hepatogastroenterology (2002) 49:1571-1575.
53. GEIER DA, GEIER MR: Cutaneous immunologic reactions and hepatitis B virus vaccine. Ann. Intern. Med. (2002) 136:780-781.
54. GEIER MR, GEIER DA: Vaccine causation of selected adverse reactions: epidemiology of the Vaccine Adverse Event Reporting System (VAERS). Thimerosal & Vaccines (2002) 1(1):32-42.
55. GEIER DA, GEIER MR: Chronic reactions associated with hepatitis B vaccination. Ann. Pharmacother. (2002) 36:1970-1971.
56. GEIER MR, GEIER DA: Reply: hepatitis B vaccination safety. Ann. Pharmacother. (2002) 36:1649-1650.
57. GEIER DA, GEIER MR: A one year followup of chronic arthritis following rubella and hepatitis B vaccination based upon analysis of the Vaccine Adverse Events Reporting System (VAERS) database. Clin. Exp. Rheumatol. (2002) 20:767-771.